Navidea secures U.S. patent for DAT tracer, eyes Phase III trials

11/17/2013 | Pharmaceutical Business Review Online

Navidea Biopharmaceuticals has received a U.S. patent for its radiolabeled agent that binds to dopamine transporter receptors. The patent for NAV5001 covers the formulation of the tracer, which is used with SPECT to diagnose Parkinsonian syndromes and dementia with Lewy bodies. Phase III clinical trials of NAV5001 are expected to start by the end of the year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ